Analysts think CTSO stock price could increase by 201%
Jul 31, 2024, 6:26 AM
-13.92%
What does CTSO do
CytoSorbents Corp., based in Princeton, New Jersey, specializes in critical care immunotherapy and blood purification technology, having launched its IPO in 2005. The company's flagship product, CytoSorb, aims to mitigate cytokine storms in severe medical conditions, alongside other products and candidates like VetResQ and DrugSorb-ATR.
6 analysts think CTSO stock price will increase by 201.27%. The current median analyst target is $3.57 compared to a current stock price of $1.19. The lowest analysts target is $1.01 and the highest analyst target is $6.83.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.